Serum S100β protein as a marker of disease activity in patients with malignant melanoma

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Medical Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1385/MO:18:2:109
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma.

  2001cited by this paper
• A new American Joint Committee on Cancer staging system for cutaneous melanoma

  2000cited by this paper
• S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.

  1999cited by this paper
• Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients.

  1999cited by this paper
• Detection of tyrosinase mRNA by RT-PCR in the peripheral blood of patients with advanced metastatic melanoma.

  1999cited by this paper
• Clinical and prognostic relevance of serum S‐100β protein in malignant melanoma

  1998cited by this paper
• 2nd International Conference on the Adjuvant Therapy of Malignant Melanoma. London, UK, 14-15 March, 1997. Report and abstracts.

  1997cited by this paper
• Serum S100--a marker for disease monitoring in metastatic melanoma.

  1997cited by this paper
• Serum S-100 Protein, Relationship to Clinical Outcome in Acute Stroke

  1997cited by this paper
• Systemic treatment of malignant melanoma: grade is as important as stage

  1997cited by this paper
• Serum S‐100 protein: a potentially useful prognostic marker in cutaneous melanoma

  1997cited by this paper
• Serial S-100 protein serum measurements related to early magnetic resonance imaging after minor head injury. Case report.

  1996cited by this paper
• Taxol and vinorelbine: a new active combination for disseminated malignant melanoma

  1996cited by this paper
• Clinical significance of serum S100 in metastatic malignant melanoma.

  1995cited by this paper
• Melanoma-associated antigens.

  1993cited by this paper
• Perspectives in S-100 protein biology. Review article.

  1991cited by this paper
• S‐100 PROTEIN AS A MARKER FOR MELANOCYTIC AND OTHER TUMOURS

  1985cited by this paper
• Immunohistochemical demonstration of S 100 protein in malignant melanoma and pigmented nevus, and its diagnostic application

  1982cited by this paper

• Reconsidering S100B: Why it is time to abandon its use in detecting disease recurrence in stage III melanoma patients.

  2024cites this paper
• Diagnostic performance of early increase in S100B or LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma.

  2022cites this paper
• Predictive Performance of Serum S100B Versus LDH in Melanoma Patients: A Systematic Review and Meta-Analysis

  2021cites this paper
• Monthly changes in serum levels of S100B protein as a predictor of metastasis development in high‐risk melanoma patients

  2020cites this paper
• S‐100B as an extra selection tool for FDG PET/CT scanning in follow‐up of AJCC stage III melanoma patients

  2019cites this paper
• Longitudinal serum S100β and brain aging in the Lothian Birth Cohort 1936

  2018cites this paper
• Journal of Surgical Oncology

  2017cites this paper
• Metastatic pathways in patients with cutaneous melanoma

  2017cites this paper
• Melanoma m1: diagnosis and therapy.

  2014cites this paper
• Melanoma m 1 : Diagnosis and Therapy

  2014cites this paper
• Diagnostic and Prognostic Biomarkers in Cutaneous Melanoma

  2014cites this paper
• s100β und Homocystein im Serum von stationär behandelten alkoholabhängigen Patienten als Verlaufsvariablen des akuten Alkoholentzugssyndroms

  2013cites this paper
• Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy

  2013cites this paper
• 18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma

  2013cites this paper
• Pattern of S 100-release in benign and malignant diseases beside malignant melanoma

  2013cites this paper
• The current status of S-100B as a biomarker in melanoma.

  2012cites this paper
• Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma: An Overview

  2012cites this paper
• Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis

  2012cites this paper
• Progress but not enough: the 2009 (7th) revision of the American Joint Committee on Cancer (AJCC) for melanoma staging and classification.

  2011cites this paper
• Use of S-100B to Evaluate Therapy Effects during Bevacizumab Induction Treatment in AJCC Stage III Melanoma

  2011cites this paper
• Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma

  2011cites this paper
• Optimal follow-up for melanoma

  2010cites this paper
• Interaction of developmental transcription factor HOXC11 with steroid receptor coactivator SRC-1 mediates resistance to endocrine therapy in breast cancer [corrected].

  2010cites this paper
• Lentigos, Melanocytic Naevi and Melanoma

  2010cites this paper
• Optimal follow-up for

  2010cites this paper
• Interaction of Developmental Transcription Factor HOX11 with Steroid Receptor Coactivator SRC-1 Mediates Resistance to Endocrine Therapy in Breast Cancer

  2010cites this paper
• S-100B Concentrations Predict Disease-Free Survival in Stage III Melanoma Patients

  2009cites this paper
• Adjuvant treatment with vindesine for metastatic melanoma: in response to the study of Eigentler et al. (2008).

  2009cites this paper
• Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients

  2009cites this paper
• Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694.

  2009cites this paper
• Baseline Staging of Melanoma with Unknown Primary Site: The Value of Serum S100 Protein and Positron Emission Tomography

  2008cites this paper
• Prognostic Significance and Diagnostic Value of Protein S-100 and Tyrosinase in Patients With Malignant Melanoma

  2008cites this paper
• The prognostic value of serum S100B in patients with cutaneous melanoma: A meta‐analysis

  2008cites this paper
• Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma.

  2007cites this paper
• Protein S100 as Prognostic Marker for Gastrointestinal Stromal Tumors: A Clinicopathological Risk Factor Analysis

  2007cites this paper
• The grateful dead: damage‐associated molecular pattern molecules and reduction/oxidation regulate immunity

  2007cites this paper
• Reflecting on the 2001 American Joint Committee on Cancer Staging System for melanoma.

  2007cites this paper
• Interleukin-1 Family of Cytokines and Cancer

  2007cites this paper
• Protein Biomarkers in Serum of Pediatric Patients with Severe Traumatic Brain Injury Identified by ICAT–LC-MS/MS

  2007cites this paper
• Integration of gamma knife surgery in the management of cerebral metastases from melanoma

  2006cites this paper
• Luminometrische Bestimmung von Protein S100 bei malignem Melanom

  2006cites this paper
• Die aktualisierten schweizerischen Richtlinien zur Behandlung des kutanen Melanoms - wo stehen wir heute?

  2006cites this paper
• Detection of Melanoma Relapse: First Comparative Analysis on Imaging Techniques versus S100 Protein

  2006cites this paper
• Recognition of the tumor suppressor protein p53 and other protein targets by the calcium-binding protein S100B.

  2006cites this paper
• Multicenter evaluation of the analytical and clinical performance of the Elecsys ® S100 immunoassay in patients with malignant melanoma

  2005cites this paper
• [Experiences with the new American Joint Committee on Cancer (AJCC) classification of cutaneous melanoma].

  2005cites this paper
• Cutaneous melanoma: baseline and ongoing laboratory evaluation

  2005cites this paper
• Prognostic Value of Serum S-100B in Malignant Melanoma

  2004cites this paper
• S100 serum level: a tumour marker for metastatic melanoma.

  2003cites this paper
• Evaluation of the serum l-dopa/l-tyrosine ratio as a melanoma marker

  2003cites this paper
• Reference values for serum S-100B protein depend on the race of individuals.

  2003cites this paper
• Cluster analysis of serum proteins in malignant cutaneous melanoma: search for disease markers.

  2003cites this paper
• Diagnostic value and prognostic significance of protein S‐100β, melanoma‐inhibitory activity, and tyrosinase/MART‐1 reverse transcription‐polymerase chain reaction in the follow‐up of high‐risk melanoma patients

  2003cites this paper
• Early detection of melanoma: the best strategy for a favorable prognosis.

  2002cites this paper
• Increased S100B serum levels in diffuse dermatitis.

  2002cites this paper
• Overexpression of HER-2 in thick melanoma

  2002cites this paper
• Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma

  2002cites this paper